Zobrazeno 1 - 10
of 5 216
pro vyhledávání: ''
Autor:
Andrea B. Apolo, Gopa Iyer, Srikala S. Sridhar, Pooja Ghatalia, Daniel Girardi, Parminder Singh
Publikováno v:
Urologic Oncology: Seminars and Original Investigations. 41:39-47
Bladder cancer is an aggressive and lethal disease. Even when presenting as localized muscle-invasive disease, the 5-year survival rate is about 70%, and the recurrence rate after radical cystectomy is approximately 50%. Neoadjuvant chemotherapy (NAC
News on immune checkpoint inhibitors as immunotherapy strategies in adult and pediatric solid tumors
Publikováno v:
Seminars in Cancer Biology. 79:18-43
Immune checkpoint inhibitors (ICIs) have shown unprecedented benefits in various adult cancers, and this success has prompted the exploration of ICI therapy even in childhood malignances. Although the use of ICIs as individual agents has achieved dis
Autor:
Ursa Brown-Glaberman, Hannah M. Linden, Lynn Symonds, Jennifer M. Specht, Eve T. Rodler, Isaac C. Jenkins, Xiaoyu Chai, Georgiana K. Ellis, Pavani Chalasani, Jinny Riedel, Brenda F. Kurland, Julie Gralow, Alison Stopeck, Qian Wu, Vijayakrishna V K Gadi
Publikováno v:
Clin Breast Cancer
INTRODUCTION Neoadjuvant chemotherapy is standard treatment for locally advanced (LABC) or inflammatory breast cancer (IBC). We hypothesized adding sunitinib, a tyrosine kinase inhibitor with anti-tumor and anti-angiogenic activity, to an anthracycli
Publikováno v:
European Urology Oncology. 4:943-947
Immune checkpoint inhibitors are the standard-of-care front-line treatment option for PD-L1-positive, cisplatin-ineligible metastatic urothelial carcinoma. The data supporting this are based on two single-arm trials. Randomised trials to confirm thes
Autor:
Isamu Okamoto, Tatsuo Ohira, Nobuyuki Yamamoto, Hidehito Horinouchi, Toyoaki Hida, Shinji Atagi, Tatsuro Fukuhara, Miyako Satouchi, Kazuma Kishi, Shunichi Sugawara, Shi Rong Han, Hideo Saka, Victoria Ebiana, Katsuyuki Hotta, Keisuke Aoe, Kazuhiko Nakagawa, Hiroshi Sakai, Hiroaki Okamoto, Kazuo Noguchi, Kaname Nosaki, Atsushi Horiike, Shigeki Umemura, Toshiaki Takahashi, Takayasu Kurata, Nobuyuki Katakami, Akimasa Sekine
Publikováno v:
Cancer Science
Cancer Sci
Cancer Sci
This prespecified subanalysis of the global, randomized controlled phase III KEYNOTE‐024 study of pembrolizumab vs chemotherapy in previously untreated metastatic non‐small‐cell lung cancer without EGFR/ALK alterations and a programmed death li
Autor:
Mina Samir Erian Hanna, Aminah Jatoi, Nichole A. Martin, Samantha Mannion, Yahya Almodallal, Phuong L. Nguyen, Kathryn D. Cook
Publikováno v:
Journal of Geriatric Oncology. 12:1220-1224
Background Metastatic cancer in nonagenarians and those older is rare and understudied. Here we explored whether these patients appear to benefit from antineoplastic therapy and whether outcomes differ based on whether or not untreated patients had a
Autor:
Halil Kara, Mustafa Tukenmez, Hasan Karanlik, A.K. Polat, Levent Yeniay, Abdullah Igci, Selman Emiroğlu, Y.E. Ersoy, Adnan Aydiner, G. Çakmak Karadeniz, Baha Zengel, Cihan Uras, N. Yıldırım, Kamuran Ibis, Vahit Özmen, Mahmut Muslumanoglu, Neslihan Cabioglu, D. Trabulus Can, Enver Ozkurt
Publikováno v:
European Journal of Surgical Oncology. 47:2506-2514
Purpose: Factors affecting local outcome were evaluated in patients with clinically node-positive (cN+) breast cancer at diagnosis, who underwent sentinel lymph node biopsy (SLNB) alone after neoadjuvant chemotherapy (NAC). Methods: Between 2004 and
Autor:
Amir Ashrafi-Zadeh, Connie I. Diakos, Andrew Kneebone, Anthony J. Gill, Nick Pavlakis, David Chan, Stephen Clarke, Asanka R. Wijetunga, Jaswinder S. Samra, Terence C. Chua, George Hruby, Christopher B. Nahm, Sarah Maloney, Nigel B. Jamieson, Anubhav Mittal
Publikováno v:
European Journal of Surgical Oncology. 47:2543-2550
Background Pancreatic cancer is the 8th commonest cancer and the 5th commonest cause of cancer-related death in Australia, with a 9% average 5-year survival. This study aims to investigate the effects of neoadjuvant treatment on overall survival (OS)
Autor:
Atanas Ignatov, Piotr Czapiewski, Thomas Kalinski, Willi Pieper, Norbert Nass, Johannes Haybaeck
Publikováno v:
Cancer Biomarkers. 32:161-173
BACKGROUND: Neuronatin (NNAT) determined by immunohistochemistry is a negative prognostic biomarker for breast cancer, independent of the major clinicopathological markers. OBJECTIVE: Here, we investigated whether NNAT is also a predictive biomarker
Publikováno v:
Journal of Geriatric Oncology. 12:1114-1117
Background The PIK3 kinase inhibitor, alpelisib, is a new breast cancer drug that can cause hyperglycemia, which can be especially severe in older patients. Yet, to our knowledge, no prior studies have sought to understand what older patients experie